- Home
- CAAP vs APLS Comparison
CAAP vs APLS Comparison
Compare CAAP & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- APLS
- Stock Information
- Founded
- CAAP 1998
- APLS 2009
- Country
- CAAP Luxembourg
- APLS United States
- Employees
- CAAP N/A
- APLS N/A
- Industry
- CAAP Aerospace
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- APLS Health Care
- Exchange
- CAAP Nasdaq
- APLS Nasdaq
- Market Cap
- CAAP 3.2B
- APLS 3.6B
- IPO Year
- CAAP 2018
- APLS 2017
- Fundamental
- Price
- CAAP $18.65
- APLS $27.52
- Analyst Decision
- CAAP Strong Buy
- APLS Buy
- Analyst Count
- CAAP 1
- APLS 18
- Target Price
- CAAP $21.50
- APLS $46.71
- AVG Volume (30 Days)
- CAAP 101.3K
- APLS 1.5M
- Earning Date
- CAAP 03-19-2025
- APLS 02-28-2025
- Dividend Yield
- CAAP N/A
- APLS N/A
- EPS Growth
- CAAP 115.99
- APLS N/A
- EPS
- CAAP 2.09
- APLS N/A
- Revenue
- CAAP $1,496,122,000.00
- APLS $715,216,000.00
- Revenue This Year
- CAAP $22.50
- APLS $97.25
- Revenue Next Year
- CAAP $13.47
- APLS $12.68
- P/E Ratio
- CAAP $8.95
- APLS N/A
- Revenue Growth
- CAAP N/A
- APLS 162.10
- 52 Week Low
- CAAP $13.74
- APLS $24.34
- 52 Week High
- CAAP $20.79
- APLS $71.90
- Technical
- Relative Strength Index (RSI)
- CAAP 42.42
- APLS 38.99
- Support Level
- CAAP $18.62
- APLS $26.84
- Resistance Level
- CAAP $19.85
- APLS $28.59
- Average True Range (ATR)
- CAAP 0.67
- APLS 1.12
- MACD
- CAAP -0.05
- APLS -0.03
- Stochastic Oscillator
- CAAP 2.19
- APLS 18.09
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.